Annexin II variant compositions and methods
This disclosure describes polypeptides fragments of annexin II, variants thereof, compositions that includes such fragments and/or variants, and methods of using such frag and/or variants.
1. A composition comprising an immunomodulatory annexin II variant comprising:
a domain corresponding to amino acids 1-15 of SEQ ID NO:1, the domain comprising:
at least one amino acid substitution compared to amino acids 1-15 of SEQ ID NO:1; and
no more than two amino acid substitutions compared to amino acids 1-15 of SEQ ID NO:1.
2. The composition of claim 1 further comprising at least one antigen.
3. The composition of claim 1 further comprising a second immunomodulatory component, the second immunomodulatory component comprising an adjuvant.
4. The composition of claim 2 , wherein the antigen is coupled to the annexin II variant.
5. The composition of claim 1 further comprising a targeting moiety coupled to the annexin II variant.
6. The composition of claim 1 further comprising a stabilizing moiety coupled to the annexin II variant.
7. The composition of claim 4 , wherein the coupling comprises a covalent coupling.
8. The composition of claim 7 , wherein the covalent coupling comprises a covalent crosslink between the at least one annexin II variant and the antigen.
9. The composition of claim 7 , wherein the covalent coupling comprises a polypeptide fusion between the at least one annexin II variant and the antigen.
10. The composition of claim 4 , wherein the coupling comprises an affinity coupling.
11. The composition of claim 3 wherein the second immunomodulatory component is coupled to the annexin II variant.
12. The composition of claim 5 wherein the coupling comprises a covalent coupling.
13. The composition of claim 5 wherein the coupling comprises an affinity coupling.
14. The composition of claim 6 wherein the coupling comprises a covalent coupling.
15. The composition of claim 6 wherein the coupling comprises an affinity coupling.
16. The composition of claim 1 farther comprising a pharmaceutically acceptable carrier.
17. A method comprising:
administering to a subject in need of such treatment an effective amount of a composition comprising an annexin II variant, the annexin II variant comprising:
a domain corresponding to amino acids 1-15 of SEQ ID NO:1, the domain comprising:
at least one amino acid substitution compared to amino acids 1-15 of SEQ ID NO:1; and
no more than two amino acid substitutions compared to amino acids 1-15 of SEQ ID NO:1.
18. A method comprising:
contacting dendritic cells with a composition comprising:
an annexin II variant comprising:
a domain corresponding to amino acids 1-15 of SEQ ID NO:1, the domain comprising:
at least one amino acid substitution compared to amino acids 1-15 of SEQ ID NO:1; and
no more than two amino acid substitutions compared to amino acids 1-15 of SEQ ID NO:1; and
an antigen.
19. The method of claim 18 further comprising administering the dendritic cells to a subject.